Moffitt researchers identify metastasis driver in BRAF inhibitor resistant melanoma

Source: Science Codex, September 2020

TAMPA, Fla. — Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.

However, many patients become resistant to the therapy, and this can often lead to further metastasis.

Moffitt Cancer Center researchers who helped develop this type of combination therapy are now working to better understand what leads to this resistance in hopes of developing ways to overcome it.

READ THE ORIGINAL FULL ARTICLE